Kathryn M. Schak, MD

JCP
Ketamine vs Esketamine for TRD
Original Research

February 1, 2023

Are ketamine and esketamine equally efficacious? This observational study compares the efficacy of subanesthetic intravenous ketamine with that of intranasal esketamine for treatment-resistant depression in a real-world clinical setting.
Balwinder Singh, Simon Kung, Vanessa Pazdernik, et al
PCC
Original Research

June 10, 2021

This study compared outcomes among newborns of opioid-using and nonopioid drug–using mothers with those of control mothers who did not report substance use. Read on to find out more.
Kriti D. Gandhi, Kathryn M. Schak, Jennifer L. Vande Voort, et al
JCP
Letter to the Editor

November 12, 2019

Few studies have evaluated optimal dosing of intravenous (IV) ketamine for treatment-resistant depression (TRD). This report analyzes data from previous studies of IV ketamine to assess the association between...
Balwinder Singh, William V. Bobo, Keith G. Rasmussen, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe